
Intranasal Vaccine Brain Risk: The 2026 BPL-1357 Policy Playing Out
The scientific case for pausing NIAID's intranasal whole-virus platforms: direct olfactory-nerve access to the brain, full structural proteins …

The scientific case for pausing NIAID's intranasal whole-virus platforms: direct olfactory-nerve access to the brain, full structural proteins …
The 18.5-day onset-to-death interval comes from a hospital inpatient cohort, not nursing homes. Care-home datasets show different intervals (11 and 22 …

A graded source register for the COVID-19 response questions: PCR cycle-threshold limits, adverse-event reporting systems and their documented …